Ibrutinib‐associated rash: a single‐centre experience of clinicopathological features and management
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2018-01, Vol.180 (1), p.164-166 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 166 |
|---|---|
| container_issue | 1 |
| container_start_page | 164 |
| container_title | British journal of haematology |
| container_volume | 180 |
| creator | Iberri, David J. Kwong, Bernice Y. Stevens, Laurel A. Coutre, Steven E. Kim, Jinah Sabile, Jean M. Advani, Ranjana H. |
| description | |
| doi_str_mv | 10.1111/bjh.14302 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1980692860</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1980692860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3882-52693fbcd0515c0e7aacdf802781952537be71b8c4bf1301857a9f1c86ad7fc63</originalsourceid><addsrcrecordid>eNp1kE1OwzAQhS0EouVnwQWQJVYs0tpxEjvsoAJaVIkNrCPbGTep8lPsRNAdR-CMnARDCjtmM4v53puZh9AZJRPqa6rWxYRGjIR7aExZEgchjeg-GhNCeEBJJEboyLk1IZSRmB6iUchjlvI0GqNioWzflU2pPt8_pHOtLmUHObbSFVdYYlc2qwr8TEPTWcDwtgFbQqMBtwbryit1u5Fd0VbtqtSywgZk11twWDY5rmUjV1B77Qk6MLJycLrrx-j57vZpNg-Wj_eL2fUy0EyIMIjDJGVG6dwfGmsCXEqdG0FCLmgahzHjCjhVQkfK-G-oiLlMDdUikTk3OmHH6GLw3dj2pQfXZeu2t41fmdFUkCQNRUI8dTlQ2rbOWTDZxpa1tNuMkuw708xnmv1k6tnznWOvasj_yN8QPTAdgNeygu3_TtnNw3yw_ALzPoNH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1980692860</pqid></control><display><type>article</type><title>Ibrutinib‐associated rash: a single‐centre experience of clinicopathological features and management</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Free Content</source><creator>Iberri, David J. ; Kwong, Bernice Y. ; Stevens, Laurel A. ; Coutre, Steven E. ; Kim, Jinah ; Sabile, Jean M. ; Advani, Ranjana H.</creator><creatorcontrib>Iberri, David J. ; Kwong, Bernice Y. ; Stevens, Laurel A. ; Coutre, Steven E. ; Kim, Jinah ; Sabile, Jean M. ; Advani, Ranjana H.</creatorcontrib><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.14302</identifier><identifier>PMID: 27539794</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biopsy ; Disease Management ; Exanthema ; Exanthema - diagnosis ; Exanthema - etiology ; Exanthema - therapy ; Hematology ; Humans ; ibrutinib ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; new leukaemia drugs ; new lymphoma drugs ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Pyrazoles - adverse effects ; Pyrazoles - therapeutic use ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Severity of Illness Index ; skin toxicity ; Symptom Assessment</subject><ispartof>British journal of haematology, 2018-01, Vol.180 (1), p.164-166</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>Copyright © 2018 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3882-52693fbcd0515c0e7aacdf802781952537be71b8c4bf1301857a9f1c86ad7fc63</citedby><cites>FETCH-LOGICAL-c3882-52693fbcd0515c0e7aacdf802781952537be71b8c4bf1301857a9f1c86ad7fc63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.14302$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.14302$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,1428,27905,27906,45555,45556,46390,46814</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27539794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iberri, David J.</creatorcontrib><creatorcontrib>Kwong, Bernice Y.</creatorcontrib><creatorcontrib>Stevens, Laurel A.</creatorcontrib><creatorcontrib>Coutre, Steven E.</creatorcontrib><creatorcontrib>Kim, Jinah</creatorcontrib><creatorcontrib>Sabile, Jean M.</creatorcontrib><creatorcontrib>Advani, Ranjana H.</creatorcontrib><title>Ibrutinib‐associated rash: a single‐centre experience of clinicopathological features and management</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biopsy</subject><subject>Disease Management</subject><subject>Exanthema</subject><subject>Exanthema - diagnosis</subject><subject>Exanthema - etiology</subject><subject>Exanthema - therapy</subject><subject>Hematology</subject><subject>Humans</subject><subject>ibrutinib</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>new leukaemia drugs</subject><subject>new lymphoma drugs</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrazoles - adverse effects</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Severity of Illness Index</subject><subject>skin toxicity</subject><subject>Symptom Assessment</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1OwzAQhS0EouVnwQWQJVYs0tpxEjvsoAJaVIkNrCPbGTep8lPsRNAdR-CMnARDCjtmM4v53puZh9AZJRPqa6rWxYRGjIR7aExZEgchjeg-GhNCeEBJJEboyLk1IZSRmB6iUchjlvI0GqNioWzflU2pPt8_pHOtLmUHObbSFVdYYlc2qwr8TEPTWcDwtgFbQqMBtwbryit1u5Fd0VbtqtSywgZk11twWDY5rmUjV1B77Qk6MLJycLrrx-j57vZpNg-Wj_eL2fUy0EyIMIjDJGVG6dwfGmsCXEqdG0FCLmgahzHjCjhVQkfK-G-oiLlMDdUikTk3OmHH6GLw3dj2pQfXZeu2t41fmdFUkCQNRUI8dTlQ2rbOWTDZxpa1tNuMkuw708xnmv1k6tnznWOvasj_yN8QPTAdgNeygu3_TtnNw3yw_ALzPoNH</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Iberri, David J.</creator><creator>Kwong, Bernice Y.</creator><creator>Stevens, Laurel A.</creator><creator>Coutre, Steven E.</creator><creator>Kim, Jinah</creator><creator>Sabile, Jean M.</creator><creator>Advani, Ranjana H.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201801</creationdate><title>Ibrutinib‐associated rash: a single‐centre experience of clinicopathological features and management</title><author>Iberri, David J. ; Kwong, Bernice Y. ; Stevens, Laurel A. ; Coutre, Steven E. ; Kim, Jinah ; Sabile, Jean M. ; Advani, Ranjana H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3882-52693fbcd0515c0e7aacdf802781952537be71b8c4bf1301857a9f1c86ad7fc63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biopsy</topic><topic>Disease Management</topic><topic>Exanthema</topic><topic>Exanthema - diagnosis</topic><topic>Exanthema - etiology</topic><topic>Exanthema - therapy</topic><topic>Hematology</topic><topic>Humans</topic><topic>ibrutinib</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>new leukaemia drugs</topic><topic>new lymphoma drugs</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrazoles - adverse effects</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Severity of Illness Index</topic><topic>skin toxicity</topic><topic>Symptom Assessment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iberri, David J.</creatorcontrib><creatorcontrib>Kwong, Bernice Y.</creatorcontrib><creatorcontrib>Stevens, Laurel A.</creatorcontrib><creatorcontrib>Coutre, Steven E.</creatorcontrib><creatorcontrib>Kim, Jinah</creatorcontrib><creatorcontrib>Sabile, Jean M.</creatorcontrib><creatorcontrib>Advani, Ranjana H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iberri, David J.</au><au>Kwong, Bernice Y.</au><au>Stevens, Laurel A.</au><au>Coutre, Steven E.</au><au>Kim, Jinah</au><au>Sabile, Jean M.</au><au>Advani, Ranjana H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibrutinib‐associated rash: a single‐centre experience of clinicopathological features and management</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2018-01</date><risdate>2018</risdate><volume>180</volume><issue>1</issue><spage>164</spage><epage>166</epage><pages>164-166</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>27539794</pmid><doi>10.1111/bjh.14302</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2018-01, Vol.180 (1), p.164-166 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_journals_1980692860 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Free Content |
| subjects | Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biopsy Disease Management Exanthema Exanthema - diagnosis Exanthema - etiology Exanthema - therapy Hematology Humans ibrutinib Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy new leukaemia drugs new lymphoma drugs Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Severity of Illness Index skin toxicity Symptom Assessment |
| title | Ibrutinib‐associated rash: a single‐centre experience of clinicopathological features and management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A29%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibrutinib%E2%80%90associated%20rash:%20a%20single%E2%80%90centre%20experience%20of%20clinicopathological%20features%20and%20management&rft.jtitle=British%20journal%20of%20haematology&rft.au=Iberri,%20David%20J.&rft.date=2018-01&rft.volume=180&rft.issue=1&rft.spage=164&rft.epage=166&rft.pages=164-166&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.14302&rft_dat=%3Cproquest_cross%3E1980692860%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1980692860&rft_id=info:pmid/27539794&rfr_iscdi=true |